57473-32-2

Basic information

• Product Name: 5,7-DICHLORO-IMIDAZO[1,2-A]PYRIMIDINE
• Synonyms: 5,7-Dichloroimidazo[1,2-a]pyrimidine hydrochloride salt;5,7-DICHLORO-IMIDAZO[1,2-A]PYRIMIDINE;5,7-Dichloroimidazo[1,2-α]pyrimidine;Zinc04204219
• CAS NO: 57473-32-2
• Molecular Formula: C6H3Cl2N3
• Molecular Weight: 188.01
• Product Categories: Heterocycle-Pyrimidine series;Heterocyclic Compounds;Bases & Related Reagents;Heterocycles;Nucleotides
• Mol File: 57473-32-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 257-259°C
• Appearance: Light Yellow Solid
• Density: 1.69
• Refractive Index: 1.733
• Storage Temp.: -20°C Freezer
• Solubility: DMSO, Methanol
• PKA: 2.31±0.30(Predicted)
• CAS DataBase Reference: 5,7-DICHLORO-IMIDAZO[1,2-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-DICHLORO-IMIDAZO[1,2-A]PYRIMIDINE(57473-32-2)
• EPA Substance Registry System: 5,7-DICHLORO-IMIDAZO[1,2-A]PYRIMIDINE(57473-32-2)

Safety Data

• Hazardous Substances Data: 57473-32-2(Hazardous Substances Data)

Usage

Chemical Properties

Light Yellow Solid

InChI:InChI=1/C6H3Cl2N3/c7-4-3-5(8)11-2-1-9-6(11)10-4/h1-3H

Upstream product

• 1366126-57-9 C₆H₅N₃O₂ 
• 51647-90-6 imidazo[1,2-a]pyrimidine-5,7-diol 

Downstream Products

• 57473-33-3 7-chloro-1H-imidazo<1,2-a>pyrimidin-5-one 
• 1366126-90-0 C₁₃H₇Cl₃FN₃O 
• 1366126-28-4 C₁₈H₂₀N₄O₂ 
• 1366126-81-9 C₁₅H₁₁ClF₃N₃O 
• 1366126-35-3 C₁₉H₁₉F₃N₄O₂ 
• 1366126-27-3 C₁₇H₁₇ClN₄O₂ 
• 1366126-33-1 C₁₇H₁₆Cl₂N₄O₂ 
• 1366126-79-5 C₁₃H₈Cl₃N₃O 
• 1366126-78-4 C₁₃H₈Cl₂FN₃O 
• 1366126-77-3 C₁₃H₈Cl₃N₃O 
• 1366126-76-2 C₁₄H₉ClF₃N₃O 
• 1366126-75-1 C₁₄H₁₂ClN₃O 
• 1366126-26-2 C₁₇H₁₇ClN₄O₂ 
• 1366126-74-0 C₁₄H₁₂ClN₃O 

Relevant articles and documents

LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF

Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists

To identify structurally novel CRF1 receptor antagonists, a series of bicyclic core antagonists, pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a] pyrimidines, imidazo[1,2-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines were designed, synthesized and evaluated as CRF1 receptor antagonists. Compounds 2-27 showed binding affinity (IC50 = 4.2-418 nM) and antagonist activity (EC50 = 4.0-889 nM). Compound 5 was found to show oral efficacy in an Elevated Plus Maze test in rats. Further chemical modification of them led us to discovery of the tricyclic core antagonists pyrazolo[1,5-a]pyrrolo[3,2-e] pyrimidines. The discovery process of these compounds is presented, as is the study of the structure-activity relationship.